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The effects of occlusive portal vein thrombosis (PVT) on the survival of patients with cirrhosis are unknown. This was a
retrospective cohort study at a single center. The main exposure variable was the presence of occlusive PVT. The primary
outcome measure was time-dependent mortality. A total of 3295 patients were analyzed, and 148 (4.5%) had PVT. Variables
independently predictive of mortality from the time of liver transplant evaluation included age [hazard ratio (HR), 1.02; 95%
confidence interval (CI), 1.01-1.03], Model for End-Stage Liver Disease (MELD) score (HR, 1.10; 95% CI, 1.08-1.11), hepatitis
C (HR, 1.44; 95% CI, 1.24-1.68), and PVT (HR, 2.61; 95% CI, 1.97-3.51). Variables independently associated with the risk of
mortality from the time of liver transplant listing included age (HR, 1.02; 95% CI, 1.01-1.03), transplantation (HR, 0.65; 95% CI,
0.50-0.81), MELD (HR, 1.08; 95% CI, 1.06-1.10), hepatitis C (HR, 1.50; 95% CI, 1.18-1.90), and PVT (1.99; 95% CI, 1.25-3.16).
The presence of occlusive PVT at the time of liver transplantation was associated with an increased risk of death at 30 days
(odds ratio, 7.39; 95% CI, 2.39-22.83). In conclusion, patients with cirrhosis complicated by PVT have an increased risk of
death. Liver Transpl 16:83-90, 2010. © 2009 AASLD.
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Occlusive portal vein thrombosis (PVT) is a common
complication of chronic liver disease with a prevalence
ranging from 1% to 16% of patients.1-5 The occurrence
of PVT is influenced by local factors (cirrhosis with
associated liver architectural changes and increased
resistance to flow), systemic factors (acquired or inher-
ited abnormalities leading to hypercoagulability), and
the development of hepatocellular carcinoma.4,6 In the
majority of patients with cirrhosis, PVT is diagnosed on
radiographic studies as an incidental finding, although
in some patients, PVT may present with decompensa-
tion of their chronic liver disease.1,7
Importantly, the natural history of PVT in patients
with cirrhosis is largely unknown.1,7,8 Certainly, many
patients with well-compensated liver disease and PVT
do well in the long term with medical management.
Historically, patients with PVT were considered to be
at increased risk of mortality related to bleeding com-
plications, but improvements in the prophylactic
management of esophageal varices have significantly
reduced these risks.9,10 Conversely, patients with oc-
clusive PVT can be difficult to manage with respect to
ascites and hepatohydrothorax. In general, patients
who fail aggressive diuretic treatment for their ascites
or hepatohydrothorax will be referred for a transjugu-
lar intrahepatic portosystemic shunt.8,11,12 Unfortu-
nately, transjugular intrahepatic portosystemic shunts
are rarely an option for patients with PVT, and as a
result, these patients may require frequent paracente-
sis or thoracentesis.
Within this context, our hypothesis is that occlusive
PVT is associated with inferior survival in patients with
chronic liver disease. This hypothesis is based on our
anecdotal, clinical experience that patients with occlu-
sive PVT and clinical decompensation have a higher
risk of infectious complications and death. Unfortu-
nately, there is little previous work focusing on the
natural history of patients with cirrhosis and PVT. To
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address this issue, we report on the survival of over
3000 adult patients with chronic liver disease who were
evaluated for a liver transplant and stratified by the
presence of occlusive PVT.
PATIENTS AND METHODS
This study was approved by the institutional review
board at the University of Michigan. We used a 100%
sample of all adult patients with cirrhosis evaluated in
the multidisciplinary liver transplant clinic at our cen-
ter between January 1, 1995 and March 30, 2007 who
had not previously undergone transplantation. Data
were obtained from a prospectively collected transplant
database and from a review of the medical record. Pa-
tients with hepatocellular carcinoma were eliminated
from all survival analyses. This was a clinical decision
based on the observation that PVT in the setting of
hepatocellular cancer is physiologically and clinically
different from PVT in the setting of cirrhosis. Patients
who received a liver transplant and were noted to have
incidental hepatocellular carcinoma were not elimi-
nated from the survival analysis. The Model for End-
Stage Liver Disease (MELD) score at the time of evalu-
ation, listing, and transplantation was calculated for
each patient with primary laboratory data from our
transplant database.
PVT is defined as occlusive thrombosis of the main
portal vein. Most patients were initially diagnosed with
PVT on liver ultrasound, but all cases were confirmed in
1 of 3 ways: a dedicated liver magnetic resonance im-
aging study, percutaneous mesenteric venography (an
angiographic procedure), or identification in the oper-
ating room at the time of the liver transplant operation.
Partially occluding thrombus in the portal vein was not
considered PVT. In addition, an occlusive thrombus in
the right portal vein, left portal vein, splenic vein, or
superior mesenteric vein was not considered PVT un-
less there was an occlusive thrombus in the main portal
vein.
Analysis
We first determined patient-specific risk factors for
PVT. For this analysis, the primary outcome measure
was time-dependent PVT. Patients were censored at the
diagnosis of PVT, transplant, or death. Using a univar-
iate Cox regression, we determined candidate covari-
ates for a multivariate model. All candidate covariates
reaching a statistical limit of significance of P  0.10, in
addition to other clinically important covariates, were
entered into the multivariate model to determine vari-
ables independently associated with a diagnosis of PVT.
For this analysis, patients with the diagnosis of cancer
were included.
A patient level analysis was performed, with the main
exposure variable being the presence of PVT, which was
treated as a time-dependent variable. The primary out-
come variable was mortality.
Among patients with and without PVT, we compared
patient age, race, diagnosis, mean follow-up, listing
rate, transplant rate, and unadjusted survival at the
end of follow-up. These univariate analyses were com-
pleted with chi-square analysis for categorical variables
and an unpaired t test for continuous variables.
Mortality rates were calculated for all patients by the
Kaplan-Meier method, and statistical differences were
determined by the log-rank test. Kaplan-Meier survival
curves were created from the time of patient evaluation
to death and from the time of transplantation to death.
Patient survival was censored at death or loss to follow-
up. Less than 1% of patients were lost to follow-up.
The independent effects of PVT on patient survival
were assessed with multivariate Cox proportional haz-
ards models. Three separate models were created to
analyze time-to-event outcomes (mortality) from the
time of liver transplant evaluation, time of listing for
liver transplantation, and time of transplantation. Po-
tential covariates for entry into the multivariate model
were determined to be clinically relevant and/or to have
a significant level in a univariate assessment of P 
0.10. Both PVT status and transplant status were
treated as time-dependent covariates. All tests used
were 2-sided, and a P value less than 0.05 was consid-
ered to be statistically significant.
The independent effects of PVT on perioperative sur-
vival (death within 30 days of liver transplantation)
were assessed with a stepwise, multivariate logistic re-
gression model.
SPSS version 15.0 (SPSS, Chicago, IL) was used for
data analysis.
RESULTS
Patient Demographics and Clinical
Management
Overall, 3897 patients were formally evaluated in liver
transplant clinics at the University of Michigan between
January 1, 1995 and March 30, 2007. Patients were
excluded from further analysis (n  602) if they did not
have chronic liver disease, were younger than 18 years
at the time of liver transplant evaluation, or had a pre-
vious liver transplant. Therefore, a total of 3295 pa-
tients met the study criteria for analysis. Of these, 148
patients (4.5%) were noted to have PVT at the time of
evaluation or during the pretransplant period.
In general, patients with PVT and patients without
PVT had similar demographics and etiologies of liver
disease (Table 1). The mean follow-up period was longer
in the PVT group (57.6  50.4 versus 49.6  42.6
months, P  0.058). At the end of the follow-up period,
54.7% of the patients with PVT had died versus 37.2%
of the patients without PVT (P  0.0001, unadjusted
analysis).
Overall, 2995 patients evaluated for liver transplan-
tation had a screening ultrasound examination to eval-
uate hepatic flow. Three hundred thirty of these pa-
tients were noted to have had an ultrasound
examination that documented either PVT (n  123) or a
suspicion thereof (n  207). Three hundred of these
patients went on to have additional imaging, and 148
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were eventually diagnosed with PVT. All 123 patients in
whom PVT was diagnosed on ultrasound were con-
firmed to have PVT on additional imaging, whereas only
20 (out of 207) with a suspicion of PVT on ultrasound
were eventually diagnosed with PVT upon additional
testing. With respect to confirmatory testing, we con-
sidered a diagnosis of PVT to be valid only when it was
diagnosed via magnetic resonance imaging, mesenteric
venography, or operative findings. Of the 148 patients
diagnosed with PVT, magnetic resonance imaging was
used to make the diagnosis in 142 cases, mesenteric
venography was used in 5 cases, and intraoperative
diagnosis was used in 1 case.
In univariate analysis, risk factors independently as-
sociated with a diagnosis of PVT included only the
MELD score at the time of evaluation [hazard ratio (HR),
1.043; 95% confidence interval (CI), 1.010-1.077; P 
0.010]. In multivariate analysis, only the MELD score
(HR, 1.060; 95% CI, 1.030-1.090; P  0.0001) and can-
cer diagnosis (HR, 3.875; 95% CI, 1.069-14.020; P 
0.039) were included.
Of the 148 patients noted to have PVT, 70 (47.3%)
were listed for transplantation (Fig. 1). In contrast,
among the 3147 patients without PVT, 1124 (35.7%)
were listed for transplantation (P  0.005). Of the 70
patients listed for transplantation with PVT, 30 (42.9%)
received a transplant versus 544 (48.4%) among the
patients listed for transplantation who did not have PVT
(P  0.390).
Overall, 71 of the patients with PVT (60.2%) who did
TABLE 1. Descriptive Statistics of Patients Evaluated for a Liver Transplant With or Without Complete Occlusion of
the Portal Vein (n  3295)
No PVT (n  3147) PVT (n  148) P Value
Gender 1905 males (60.5%) 91 males (61.5%) 0.817
Race
Black 218 (6.9%) 7 (4.7%) 0.325
Nonblack 2545 (80.9%) 131 (88.5%)
Unknown 385 (12.2%) 10 (6.8%)
Cause of liver disease
Autoimmune 95 (3.0%) 8 (5.4%) 0.138
Biliary cirrhosis 173 (5.4%) 7 (4.7%) 0.835
Cancer 62 (2.0%) 6 (4.1%) 0.125
Cryptogenic 369 (11.7%) 24 (16.2%) 0.118
EtOH 672 (21.4%) 31 (20.9%) 1.00
Hepatitis B 124 (3.9%) 8 (5.4%) 0.386
Hepatitis C 1129 (35.9%) 42 (28.7%) 0.065
NASH 72 (2.3%) 0 0.076
Other 449 (14.3%) 22 (14.9%) 0.810
Age at evaluation (years) 51.5  11.2 50.9  10.8 0.581
Age at transplant (years) 50.6  11.8 49.7  9.8 0.670
MELD at evaluation 12.1  7.2 13.3  8.3 0.245
MELD at transplant 16.5  8.3 15.2  9.0 0.985
Mean follow-up (months) 49.6  42.6 57.6  50.4 0.058
Dead at follow-up (%) 37.2% 54.7% 0.0001
Abbreviations: EtOH, ethanol; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PVT, portal vein
thrombosis.
Figure 1. Evaluation, liver
transplant listing, and trans-
plant rates among patients at
the University of Michigan with
and without portal vein throm-
bosis.
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not receive a transplant were dead at the end of follow-
up. Because of the clinical complexity of these patients,
the determination of a specific cause of death was dif-
ficult. Among patients with PVT who died in our hospi-
tal prior to transplantation (n  55), liver disease con-
tributed to the deaths of all these patients. In addition,
spontaneous bacterial peritonitis was the most com-
mon initial diagnosis (n  35, 63.6%) for the admission
during which these patients with cirrhosis and PVT
died. No PVT patients died of refractory gastrointestinal
bleeding in our institution.
Survival from the Initial Evaluation
The Kaplan-Meier analysis of patient survival from the
time of transplant evaluation, stratified by the presence
or absence of PVT, is demonstrated in Fig. 2A. Unad-
justed patient survival among those with pretransplant
PVT was significantly lower than survival among those
without PVT (P  0.007).
An additional survival analysis was completed to as-
sess the independent effects of PVT on patient survival
from the time of evaluation for liver transplantation.
Candidate variables for a multivariate model of mortal-
ity from the time of transplant evaluation were deter-
mined by univariate Cox analysis. Candidate variables
included transplantation (time-dependent; HR, 1.21;
95% CI, 1.04-1.49), race (nonwhite; HR, 1.11; 95% CI,
0.89-1.38), gender (female; HR, 1.20; 95% CI, 1.10-
1.31), age at evaluation (HR, 1.02; 95% CI, 1.01-1.03),
MELD at evaluation (HR, 1.10; 95% CI, 1.08-1.12), hep-
atitis C (HR, 1.14; 95% CI, 1.04-1.24), and PVT (HR,
2.59; 95% CI, 2.08-3.29).
The candidate variables from the univariate analysis
were used to create a multivariable Cox regression
model (Fig. 3). Variables noted to be independently as-
sociated with mortality from the time of initial liver
transplant evaluation included age at evaluation (HR,
1.02; 95% CI, 1.01-1.03), MELD at evaluation (HR,
1.10; 95% CI, 1.08-1.11), hepatitis C (HR, 1.44; 95% CI,
1.24-1.68), and PVT (HR, 2.61; 95% CI, 1.97-3.51).
In order to further describe the risk of mortality from
the time of evaluation among patients with PVT, we
compared their unadjusted mortality rate to that of
patients without PVT with stratification by the MELD
score at the time of liver transplant evaluation. Patients
with PVT had a risk of mortality similar to that of pa-
tients who presented for evaluation with a MELD score
of 26. The mean MELD score of patients with PVT at the
time of liver transplant evaluation was 12. It is impor-
tant to note that the follow-up period for the patients
with PVT was longer (57.6  50.4 versus 49.6  42.6
months, P  0.058), so their exposure to the risk of
mortality was higher.
Figure 2. Kaplan-Meier survival curves from the time of (A)
liver transplant evaluation and (B) transplantation for adult
patients with chronic liver disease stratified by the presence
of occlusive PVT.
Figure 3. Time-dependent Cox regression model of the risk of
mortality among patients who presented for evaluation for a
liver transplant. Patients with PVT had a significantly higher
risk of mortality versus patients without PVT (hazard ratio,
2.61; 95% confidence interval, 1.97-3.51). Both transplant
status and PVT were managed as time-dependent covariates
in this model. The x axis displays the hazard ratio and 95%
confidence interval for mortality. *P < 0.05.
86 ENGLESBE ET AL.
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
Survival from the Time of Listing for a Liver
Transplant
Survival analysis was completed in order to assess the
independent effects of PVT on survival from the time of
listing for a liver transplant. Candidate variables for a
multivariate model (mortality from the time of trans-
plant listing) were first determined by univariate anal-
ysis. Candidate variables included transplantation
(time-dependent; HR, 0.83; 95% CI, 0.60-1.07), race
(nonwhite; HR, 0.88; 95% CI, 0.59-1.20), sex (female;
HR, 1.15; 95% CI, 0.96-1.34), age at listing (HR, 1.01;
95% CI, 1.01-1.02), MELD at listing (HR, 1.08; 95% CI,
1.06-1.11), hepatitis C (HR, 1.22; 95% CI, 1.03-1.40),
and PVT (HR, 1.89; 95% CI, 1.28-2.49).
The candidate variables were used to create a multi-
variable Cox regression model (Fig. 4). Variables noted
to be independently associated with the hazard of mor-
tality from the time of liver transplant listing included
age at listing (HR, 1.02; 95% CI, 1.01-1.03), transplan-
tation (HR, 0.65; 95% CI, 0.50-0.81), MELD at listing
(HR, 1.08; 95% CI, 1.06-1.10), hepatitis C (HR, 1.50;
95% CI, 1.18-1.90), and PVT (HR, 1.99; 95% CI, 1.25-
3.16).
In order to further describe the risk of mortality from
the time of listing among patients with PVT, we com-
pared their unadjusted mortality rate to that of patients
without PVT with stratification by the MELD score at
the time of liver transplant listing. Patients with PVT
had a risk of mortality similar to that of patients who
presented for listing with a MELD score of 31. The mean
MELD score of patients with PVT at the time of liver
transplant listing was 14. It is important to note that
the follow-up period for the patients with PVT was
longer, so their exposure to the risk of mortality was
higher.
Survival Following a Liver Transplant
The clinical characteristics of patients with and without
PVT who received a liver transplant were similar with
respect to gender, race, cause of liver disease, and age.
The patients with PVT that received a transplant had a
significantly longer posttransplant follow-up period (79
versus 105 months, P  0.003; Table 2). MELD scores
at the time of transplant were similar between both
groups (15.1 versus 16.3, P  0.55). Survival was infe-
rior among patients with PVT after transplantation at
30 days (17.7% versus 4.4%, P  0.07), at 1 year (33.0%
versus 25.0%, P  0.354), and at follow-up (36.7%
versus 28.4%, P  0.371), but these differences were
not statistically significant (unadjusted analysis). The
causes of death among the 5 patients with PVT who
died within 30 days included primary nonfunction re-
lated to a prolonged warm ischemia time, ruptured
splenic vein varix on postoperative day 10, acute right
heart failure, intraoperative pulmonary hemorrhage,
and respiratory failure (severe pulmonary edema fol-
lowing liver transplantation after a massive transfu-
sion). Clearly, a significant portion of these early deaths
were directly attributable to PVT and the resultant dif-
ficult liver transplant operation. Among the patients
without PVT who died within 30 days (n  25), the
primary causes of death included primary nonfunction
(n  10) and right heart failure (n  8). There seems to
be a trend toward less mortality within 30 days at our
center. In the last 4 years, the 30-day survival for trans-
plants has been 98.7%, with no deaths among patients
with PVT within 30 days of transplantation. This is
likely related to technical improvements and improve-
ments in recipient and donor selection.
A multivariate logistic regression model was used to
assess independent risk factors for perioperative death
(30-day survival). The presence of occlusive PVT at the
time of liver transplantation was associated with a sig-
nificantly increased hazard of death at 30 days (odds
ratio, 7.39; 95% CI, 2.39-22.83; Table 3). Other clini-
cally relevant covariates, including age, race, sex,
MELD, and hepatitis C, were not associated with a
statistically significant increased risk of perioperative
death.
As before, a univariate Cox regression analysis was
used to generate candidate variables for a multivariate
model for survival following transplantation. In multi-
variate analysis, only the MELD score at the time of
transplantation was significantly associated with infe-
rior survival following transplantation (HR, 1.024; 95%
CI, 1.003-1.046; Fig. 5). There was a trend toward in-
ferior survival among patients with hepatitis C (HR,
1.337; 95% CI, 0.906-1.971) and PVT (HR, 1.973; 95%
CI, 0.992-3.921), but these trends were not statistically
significant. In contrast, patients with PVT were noted to
have inferior survival on Kaplan-Meier analysis (P 
0.009; Fig. 2B).
Figure 4. Time-dependent Cox regression model of the risk of
mortality among patients who were listed for liver transplan-
tation. Liver transplant candidates with PVT had a signifi-
cantly higher risk of mortality versus candidates without PVT
(hazard ratio, 1.99; 95% confidence interval, 1.25-3.16).
Both transplant status and PVT were managed as time-depen-
dent covariates in this model. The x axis displays the hazard
ratio and 95% confidence interval for mortality. *P < 0.05.
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With respect to surgical methods, an endovenotomy
was attempted in each case of PVT. In 90% of the cases
(n  27), this was successful in securing adequate por-
tal venous inflow. In 10% of the cases, it was not. Al-
ternative attempts included a superior mesenteric vein
jump graft with a vein conduit (n  1) and portocaval
transposition (n  2). Of the 3 patients in which en-
dovenotomy was not successful, all died within 1 year.
DISCUSSION
In this study, the effects of occlusive PVT on the survival
of patients with chronic liver disease were examined.
This study is the largest and most comprehensive as-
sessment of PVT in patients with cirrhosis. PVT was
found to be independently associated with inferior sur-
vival among patients with cirrhosis who are being eval-
uated for a liver transplant and associated with inferior
short-term survival following liver transplantation.
These findings may inform decisions regarding the suit-
ability and timing of transplantation for patients with
cirrhosis and PVT.
The etiology and clinical management of patients with
cirrhosis and PVT are poorly described. The expected
pathophysiological consequences of PVT include a fur-
ther increase in portal hypertension and a worsening of
liver function due to the decreased portal flow.1 Pa-
tients with cirrhosis and PVT have been shown to have
inferior survival in comparison with patients without
TABLE 2. Liver Transplant Recipients With or Without Complete Occlusion of the Main Portal Vein (n  574)
No PVT (544) PVT (n  30) P Value
Race
Black 36 (6.5%) 1 (3.3%) 0.389
Nonblack 491 (89.3%) 29 (96.7%)
Unknown 23 (4.2%) 0 (0.0%)
Age at evaluation (years) 49.3 47.5 0.358
Age at transplant (years) 50.6 49.7 0.618
Mean follow-up (months) 79.0 105 0.003
MELD at transplant 16.3 15.1 0.552
Dead at 30 days (%) 4.4 17.7 0.071
Dead at 1 year (%) 25.0 33.0 0.354
Dead at follow-up (%) 28.4 36.7 0.371
Abbreviations: MELD, Model for End-Stage Liver Disease; PVT, portal vein thrombosis.
TABLE 3. Thirty-Day Survival After Liver Transplantation
Variable P Value HR Lower CI Upper CI
Age at transplant 0.511 0.987 0.950 1.026
Hepatitis C 0.918 1.050 0.417 2.647
MELD at transplant 0.478 1.018 0.969 1.068
PVT 0.001 7.389 2.392 22.827
Male 0.891 1.068 0.413 2.761
Nonblack 0.404 0.511 0.106 2.468
Abbreviations: CI, confidence interval; HR, hazard ratio; MELD, Model for End-Stage Liver Disease; PVT, portal vein
thrombosis.
Figure 5. Time-dependent Cox regression model of the risk of
mortality among patients who received a liver transplant. Only
the MELD score at the time of Txp was significantly associ-
ated with inferior survival following Txp (hazard ratio, 1.024;
95% confidence interval, 1.003-1.046). The x axis displays
the hazard ratio and 95% confidence interval for mortality.
*P < 0.05.
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PVT, but previous work has been unable to control for
the degree of synthetic liver dysfunction.1,6,7 In addi-
tion, previous work has primarily focused on the risk of
mortality related to gastrointestinal bleeding. With ad-
vances in the management of esophageal varices, gas-
trointestinal bleeds are now a less common cause of
death among patients with cirrhosis, and in our series,
no patients with PVT who died had refractory gastroin-
testinal bleeding as the cause of death.2,4,13,14
Because access to liver transplantation in the United
States is determined by the risk of mortality on the
waitlist, a clear understanding of the independent con-
tributions of PVT to mortality among patients with cir-
rhosis is needed. This analysis has observed a signifi-
cantly increased risk of mortality among patients with
PVT, even when controlling for the MELD score. For
patients with PVT and decompensated liver disease (eg,
ascites and encephalopathy), transplantation might be
appropriate, even if the MELD score is low. The United
Network for Organ Sharing regional review boards
should carefully consider awarding MELD exception
points to clinically unstable patients with PVT.
That having been said, it is important to consider
MELD exception points for PVT within the context of the
observation that patients with PVT have inferior post-
transplant survival. Both our analysis and work com-
pleted by the Scientific Registry of Transplant Recipi-
ents have noted inferior posttransplant survival among
patients with PVT.5,15 A poor posttransplant outcome is
not a good argument for advocating for preferential ac-
cess to transplantation for patients with PVT. Accord-
ingly, patients with PVT, particularly those thought to
be at increased risk of a difficult perioperative course,
must be carefully selected for transplantation. This in-
cludes patients with significant debilitation, malnutri-
tion, advanced age, or a nonliver end-organ disease.
Overall, focusing on the benefit of liver transplantation
might address the balance between wait-list and post-
transplant survival. In all, a larger analysis using Sci-
entific Registry of Transplant Recipients data and fo-
cusing on the relative benefit of transplantation among
PVT patients compared to other patients on the wait-list
is in progress by our group and is needed to more fully
inform policy decisions regarding patients with PVT.
Although our study provides several novel insights, it
has several limitations. First, all data for this study
were obtained from a single center with a relatively
small sample (n  148) of patients with PVT. For this
analysis, it was important that PVT be managed as a
time-dependent covariate in survival models, and as a
result, a very detailed retrospective assessment of the
medical record is required. Such detailed data are not
available in any clinical registry or database, and thus
a more extensive assessment of PVT using larger data
sets is not currently possible. Second, as mentioned
earlier, PVT is poorly understood. As a result, unknown
confounding factors may exist. Similarly, the MELD
score was used to control for the degree of synthetic
liver dysfunction, but certainly a true assessment of the
severity of end-stage liver disease is more complex than
simply the MELD score. More specifically, the MELD
score was designed as a measure of liver transplant
wait-list mortality and not as a measure of synthetic
liver dysfunction. To address this with a sensitivity
analysis, we used MELD components (international
normalized ratio, creatinine, and bilirubin) in our mul-
tivariable models instead of the MELD score, and no
significant differences were noted in the model results.
Third, although we attempted to control for illness se-
verity, our methods do not fully account for the dy-
namic nature of illness severity. Ideally, the MELD
score or its components would have been treated as a
time-dependent covariate, but we were not able to do
this because of limitations of the data set. Similarly, a
small proportion of patients who were transplanted
were managed with warfarin (8% of PVT patients and
6% of non-PVT patients), and this would have elevated
these patients’ MELD scores at transplant. The PVT
patients were largely treated with warfarin for their
PVT, whereas the non-PVT patients were treated for
either venous thromboembolism or atrial arrhythmia.
Either the inclusion or exclusion of these patients from
the analysis would introduce a confounding factor, and
we have elected to include these patients in the analy-
sis. The inclusion of warfarin therapy in the posttrans-
plant models had no effect on model outputs. Another
limitation of this study is that the observation period
was from 1995 to 2007, and the study was limited to
patients who were evaluated for liver transplantation.
Certainly, the clinical management of end-stage liver
disease and liver transplantation allocation changed
significantly over this time period. For example, our
group is currently more aggressive about transplanting
patients with PVT than we were in the past. As a result,
these era effects could have implications for the conclu-
sions made on the basis of these data.
Consideration should be given to the potential impli-
cations of selection bias in this retrospective cohort.
Only patients who were referred for liver transplant
evaluation were studied. As a result, this study is an
assessment not of all patients with cirrhosis and PVT
but only of the subset of patients referred for liver trans-
plant evaluation. In addition, patients with PVT may be
more likely to be “passed over” for available organs
because of the complexity of their operation, and this
could lead to lower transplant rates and higher death
rates. Similarly, with respect to the diagnosis of PVT,
patients who were listed for a liver transplant may have
been followed more closely and, as a result, were poten-
tially more likely to receive a diagnosis of PVT. Presum-
ably, these issues with selection not only affected this
analysis but also will limit any future analysis of clinical
registry data.
In summary, patients with cirrhosis complicated by
PVT have a significantly increased risk of death. Policy-
makers and members of United Network for Organ
Sharing regional review boards must consider not only
the increased risk of pretransplant death among these
patients but also the inferior posttransplant outcomes.
Additional study is needed to clarify the management of
patients with chronic liver disease complicated by oc-
clusive PVT.
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